Hostname: page-component-8448b6f56d-xtgtn Total loading time: 0 Render date: 2024-04-20T01:16:00.179Z Has data issue: false hasContentIssue false
  • English
  • Français

Some Global Policies for Antibiotic Resistance Depend on Legally Binding and Enforceable Commitments

Published online by Cambridge University Press:  01 January 2021

Asha Behdinan ,
Steven J. Hoffman  and
Mark Pearcey
Get access Rights & Permissions [Opens in a new window]

Extract

This article assesses which policies for addressing antibiotic resistance (ABR) as part of a multi-pronged approach would benefit from legalization through an international legal agreement. Ten candidate policies were identified based on a review of existing literature, especially The Lancet Series on Antimicrobial Resistance (AMR), The Lancet Infectious Diseases Commission on AMR, and the World Health Organization (WHO) Global Action Plan for AMR. These policies were then grouped under the headings of access, conservation, and innovation.

Each of the ten policies were assessed using four criteria developed by Hoffman, Røttingen, and Frenk to help consider why their legalization may be helpful, necessary and/or justified. These criteria are: (1) the problem has a significant transnational dimension; (2) the goal justifies the coercive nature of law; (3) the outcome is likely to be beneficial; and (4) legalization represents the best commitment mechanism among competing alternatives.

Type
JLME Supplement
Information
Journal of Law, Medicine & Ethics , Volume 43 , Issue S3 , Autumn 2015 , pp. 68 - 73
Copyright
Copyright © American Society of Law, Medicine and Ethics 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ardal, C. Outterson, K. Hoffman, S. J. Ghafur, A. Sharland, M. Ranganthan, N. et al., “International Collaboration to Improve Access to and Sustain Effectiveness of Antimicrobials,” The Lancet (in press).Google Scholar
Laxminarayan, R. Duse, A. Wattal, C. Zaidi, A. K. M. Wertheim, H. F. L. Sumpradit, N. et al., “Antibiotic Resistance - The Need for Global Solutions,” The Lancet Infectious Diseases 13, no. 12 (2013): 1057–1098.CrossRefGoogle Scholar
World Health Organization: Draft Global Action Plan on Antimicrobial Resistance, World Health Organization, available at <http://www.who.int/drugresistance/AMR_DRAFT_GAP_1_Oct_2014_for_MS_consultation.pdf> (last visited May 29, 2015).+(last+visited+May+29,+2015).>Google Scholar
Hoffman, S. J. Outterson, K. Røttingen, J.-A. Cars, O. Clift, C. Rizvi, Z. et al., “An International Legal Framework to Address Antimicrobial Resistance,” Bulletin of the World Health Organization 93, no. 2 (2015): 66.CrossRefGoogle Scholar
Hoffman, S. J. Røttingen, J.-A. Frenk, J., “International Law Has a Role to Play in Addressing Antibiotic Resistance,” Journal of Law, Medicine & Ethics 43, no. 2, Supp. (2015): Available via aslme.org.Google Scholar
Hoffman, S. J. Røttingen, J.-A. Frenk, J., “Assessing Proposals for New Global Health Treaties: An Analytic Framework,” American Journal of Public Health (2015): e1–e8.CrossRefGoogle Scholar
See WHO, supra note 3.Google Scholar
Hoffman, S. J. McGrady, B. Caleo, G. M. Daulair, N. Elbe, S. Wong, D. L. F. et al., “Achieving Global Collective Action For Improving Access to Antimicrobials and Sustaining Their Effectiveness,” in preparation; Edge, J. S. Hoffman, S. J., “Empirical Impact Evaluation of the WHO Global Code of Practice on the International Recruitment of Health Personnel in Australia, Canada, UK and USA,” Globalization & Health 9, no. 60 (2013): 1–10.Google Scholar
Spellberg, B. Bartlett, J. G. Gilbert, D. N., “The Future of Antibiotics and Resistance,” New England Journal of Medicine 368, no. 4 (2013): 299–302.CrossRefGoogle Scholar
Huttner, A. Harbarth, S. Carlet, J. Cosgrove, S. Goossens, H. Holmes, A. et al., “Antimicrobial Resistance: A Global View From the 2013 World Healthcare-Associated Infections Forum,” Antimicrobial Resistance and Infection Control 2, no. 31 (2013): 1–13; Van Boeckel, T. P. Brower, C. Gilbert, M. Grenfell, B. T. Levin, S. A. Robinson, T. P. et al., “Global Trends in Antimicrobial Use in Foods,” Proceedings of the National Academy of Sciences of the United States of America 112, no. 18 (2013): 5649–5654.CrossRefGoogle Scholar
World Health Organization, The Evolving Threat of Antimicrobial Resistance, (2012), available at <http://www.who.int/patientsafety/implementation/amr/publication/en/> (last visited June 1, 2015).+(last+visited+June+1,+2015).>Google Scholar
Hoffman, S. J. Røttingen, J.-A., “Be Sparing With International Laws,” Nature 483, no. 7389 (2012): 275; Hoffman, S. J. Røttingen, J.-A., “Assessing Implementation Mechanisms For an International Agreement On Research and Development For Health Products,” Bulletin of the World Health Organization 90 (2012): 854–863; Hoffman, S. J. Ottersen, T., “Addressing Antibiotic Resistance Requires Robust International Accountability Mechanisms,” Journal of Law, Medicine & Ethics 43, no. 2, Supp. (2015): Available via aslme.org.CrossRefGoogle Scholar
Le Doare, K. Barker, C. I. S. Irwin, A. Sharland, M., “Improving Antibiotic Prescribing for Children in the Resource-Poor Setting,” British Journal of Clinical Pharmacology 79, no. 3, (2015): 446–455.CrossRefGoogle Scholar
Id.Google Scholar
Leung, E. Weil, D. E. Raviglione, M. Nakatani, H., “Policy Package to Combat Antimicrobial Resistance,” World Health Organization World Health Day Antimicrobial Resistance Technical Working Group, available at <http://www.reactgroup.org/uploads/publications/other-publications/WHO-Policy-Package-to-Combat-Antimicrobial-Resistance.pdf> (last visited June 1, 2015).CrossRef+(last+visited+June+1,+2015).>Google Scholar
See Hoffman, Røttingen, (“Assessing Implementation”), supra note 12.Google Scholar
See Leung, et al., supra note 15.Google Scholar
Vernet, G. Mary, C. Altmann, D. M. Doumbo, O. Morpeth, S. Bhutta, Z. A. et al., “Surveillance for Antimicrobial Drug Resistance in Under-Resourced Countries,” Emerging Infectious Diseases 20, no. 3 (2014): 434–441.CrossRefGoogle Scholar
Henriksen, L., “Comprehensive Tobacco Marketing Restrictions: Promotion, Packaging, Price, and Place,” Tobacco Control 21, no. 2 (2012): 147–153.CrossRefGoogle Scholar
Id.Google Scholar
Røttingen, J.-A. Chamas, C., “A New Deal for Global Health R&D? The Recommendations of the Consultative Expert Working Group on Research and Development,” PLOS Medicine 9, no. 5 (2012): e1001219.CrossRefGoogle Scholar
WHO Consultative Expert Working Group on Research and Development, “Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination,” WHO, available at <http://www.who.int/phi/cewg_report/en/> (last visited June 1, 2015); Rizvi, Z. Hoffman, S. J., “Effective Global Action on Antibiotic Resistance Requires Careful Consideration of Convening Forums,” Journal of Law, Medicine & Ethics 43, no. 2, Supp (2015): Available via aslme.org.Google Scholar
Hoffman, S. J. Røttingen, J.-A., “Assessing the Expected Impact of Global Health Treaties: Evidence from 90 Quantitative Evaluations,” American Journal of Public Health 105, no. 1 (2015): 26–40.Google Scholar